Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or Oregon for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to Oregon only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. Oregon (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

David Dryland (NPI 1205896115)

Field	Value
Entity Type	Individual
Organization	David Dryland
Address	1801 Highway 99 N Ste 2
City	Ashland
State	OR
ZIP	97520
Taxonomy	Rheumatology Physician
NPI Enumerated	March 24, 2006

Payer Source	Total Paid
Medicare	$1.4M
Medicaid	$0

Key Findings

This provider is effectively single‑payer in scope: lifetime Medicare revenue is $1.4M and there is no Medicaid billing on file. The absence of any Medicaid claims indicates the practice’s revenue and utilization patterns are driven entirely by Medicare patients in the available data set.

Revenue is highly concentrated in a small set of biologic infusion drugs: the precomputed top‑3 Medicare codes account for 52.3% of this provider’s total Medicare revenue, driven by J9312 ($260.4K, 18.9%), Q5104 ($235.8K, 17.1%), and J1745 ($225.2K, 16.3%). This concentration indicates the practice’s financial footprint is dominated by high‑cost infused biologics rather than a broad mix of office procedures.

The code mix and descriptions point to an infusion‑center or infusion‑heavy rheumatology practice: frequent billing for rituximab (J9312), infliximab and its biosimilar forms (J1745, Q5104), golimumab (J1602) and certolizumab (J0717) aligns with ongoing intravenous biologic administration and supervised infusion services. Supporting procedure codes such as 96365, 96413 and 96415 indicate in‑office infusion and chemotherapy administration workflows rather than only outpatient office visits.

The provider is a notable national outlier on several infusion‑related items: Q5104 ranks #6 of 178 providers nationally (97th percentile; notably above typical national volume) and Q5119 ranks #5 of 335 providers nationally (99th percentile; notably above typical national volume), signaling unusually high volume of biosimilar rituximab/infliximab use compared with peers. Additionally, 96415 is an extreme outlier (rank #44 of 4959, 99th percentile), suggesting above‑typical use of extended infusion/add‑on hours relative to national providers.

For some high‑cost biologics the provider’s national standing is typical-to-modest: J9312 (rituximab) generates $260.4K and ranks #102 of 317 (67th percentile; typical, unremarkable volume), and J1745 (infliximab) generates $225.2K and ranks #122 of 1352 (91th percentile; typical, unremarkable volume). These rankings suggest the practice’s position varies by drug—very high on certain biosimilars but otherwise in the middle of the pack for originator biologics.

Office evaluation and management activity is meaningful relative to national peers: 99214 accounts for $85.7K (6.2% of Medicare revenue) and ranks #10247 of 479517 (98th percentile; notably above typical national volume), indicating a substantial volume of moderate‑complexity established patient visits alongside infusion services. In contrast, lower‑level E/M 99213 is much smaller ($5.6K), implying the practice may concentrate on higher‑complexity follow‑up visits.

The overall service profile suggests integrated infusion and procedure capacity: the presence of joint injection codes (20610, 20600), intra‑articular hyaluronan (J7323), multiple IV administration codes (96365, 96413, 96375) and steroid injections (J1020, J2930) indicates the practice provides both supervised biologic infusions and office procedural care common to rheumatology specialty practices. This mix supports a business model oriented around recurring infusions plus ancillary procedural revenue.

The provider has a long NPI tenure, enumerated on 2006-03-24 (~20 years ago), which together with sustained Medicare billing and high procedure volumes for select biologics suggests an established practice with longstanding infusion services in ASHLAND, OR. Given the single‑payer concentration in Medicare and the absence of Medicaid billing, analysts should treat competitive and network assessments through the Medicare lens rather than expecting Medicaid market influence.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

25 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J9312	Injection, rituximab, 10 mg	4,200	$60	$260.4K
Q5104	Injection, infliximab-abda, biosimilar, (renflexis), 10 mg	7,860	$30	$235.8K
J1745	Injection, infliximab, excludes biosimilar, 10 mg	8,660	$30	$225.2K
J1602	Injection, golimumab, 1 mg, for intravenous use	15,670	$10	$156.7K
J0717	Injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered)	37,200	$1	$148.8K
Q5119	Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg	6,700	$20	$147.4K
99214	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the…	1,050	$80	$85.7K
96413	Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These…	380	$100	$37.3K
96365	The provider administers the initial intravenous infusion of a medication or other substance for a period up to one hour to prevent, treat, or diagnose a condition or disease.	360	$50	$17.5K
96415	In this add on procedure, the provider continues administration of a chemotherapy drug into a vein using an infusion technique. He uses this code to report each additional hour of infusion beyond the…	590	$20	$12.5K

Showing 1–10 of 25

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 25 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. Oregon Distribution

David Dryland — 8 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — Oregon

Full comparison — all codes billed, vs. state median

25 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J9312	2	10	3,750	$60	$220K
J1602	10	20	13,600	$10	$156.4K
Q5104	1	10	3,850	$30	$129.7K
J0717	1	10	30,800	$1	$117.6K
J1745	2	20	3,750	$30	$115.2K
Q5119	1	10	1,970	$20	$66.1K
96413	7	90	150	$100	$18.2K
99214	32	6,070	80	$70	$10.3K
91320	178	370	50	$130	$10.1K
J7323	16	20	60	$100	$7.4K

Showing 1–10 of 25

Nearby Providers

Other providers in the same ZIP code as David Dryland, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Asante Ashland Community Hospital, LLC	OR	General Acute Care Hospital	$0	$9M
Southern Oregon Chiropractic-ashland LLC	OR	Rehabilitation Chiropractor	$0	$2.7M
Jeffrey Welder	OR	Ophthalmology Physician	$2.3M	$0
Christine Gonzales	OR	Ophthalmology Physician	$2.1M	$0
John Hyatt	OR	Retina Specialist (Ophthalmology) Physician	$1.6M	$0
City Of Ashland	OR	Land Ambulance	$401.3K	$1.1M
Bear Creek Physical Therapy	OR	Physical Therapist	$0	$1.3M
Rogue Community Health	OR	Federally Qualified Health Center (FQHC)	$0	$1.3M
Ashland Surgery Center	OR	Ambulatory Surgical Clinic/Center	$1.2M	$3.2K
Robert Medeck	OR	Chiropractor	$8.2K	$1M

David Dryland — Billing Profile & Reimbursement Data

Sign up for David Dryland — Billing Profile & Reimbursement Data policy alerts

David Dryland — Billing Profile & Reimbursement Data

Sign up for David Dryland — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Nearby Providers

Frequently Asked Questions

References